Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
Anteris Technologies has announced successful enrollment and treatment of the first U.S. patients in its global pivotal PARADIGM clinical trial for the DurAVR® Transcatheter Heart Valve (THV), targeting severe calcific aortic stenosis. The PARADIGM Trial is a significant head-to-head randomized study comparing DurAVR® THV with currently approved tr…